ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Shares Break Above 200-Day Moving Average – Here’s What Happened

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report)’s share price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $57.12 and traded as high as $57.84. ALPS Medical Breakthroughs ETF shares last traded at $57.60, with a volume of 22,302 shares changing hands.

ALPS Medical Breakthroughs ETF Stock Performance

The company has a 50 day moving average price of $58.14 and a two-hundred day moving average price of $57.12.

Institutional Investors Weigh In On ALPS Medical Breakthroughs ETF

Several institutional investors and hedge funds have recently added to or reduced their stakes in SBIO. Phoenix Wealth Advisors increased its stake in shares of ALPS Medical Breakthroughs ETF by 33.6% during the third quarter. Phoenix Wealth Advisors now owns 11,212 shares of the company’s stock worth $654,000 after purchasing an additional 2,822 shares in the last quarter. Commonwealth Equity Services LLC acquired a new position in shares of ALPS Medical Breakthroughs ETF during the 3rd quarter worth about $688,000. NTV Asset Management LLC lifted its stake in ALPS Medical Breakthroughs ETF by 1.2% in the 3rd quarter. NTV Asset Management LLC now owns 17,283 shares of the company’s stock valued at $1,008,000 after buying an additional 200 shares in the last quarter. Sowell Financial Services LLC purchased a new position in ALPS Medical Breakthroughs ETF in the 3rd quarter valued at about $436,000. Finally, Fig Financial Advisory Services Inc. ADV purchased a new position in ALPS Medical Breakthroughs ETF in the 3rd quarter valued at about $1,759,000.

ALPS Medical Breakthroughs ETF Company Profile

(Get Free Report)

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.

Recommended Stories

Receive News & Ratings for ALPS Medical Breakthroughs ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALPS Medical Breakthroughs ETF and related companies with MarketBeat.com's FREE daily email newsletter.